• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Two Augmentation Strategies Compared in Bipolar I
RESEARCH UPDATE

Two Augmentation Strategies Compared in Bipolar I

September 3, 2020
Richard Moldawsky, MD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue

Richard J. Moldawsky, MD. Dr. Moldawsky has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Review of: Missio G et al, Trials 2019;20(1):608

STUDY TYPE: Randomized, open-label controlled trial

It’s rare to see full recovery in bipolar I disorder with a single medicine, so we often depend on some combination of mood stabilizers and/or antipsychotics. Even then, weight gain and metabolic problems are deal-breakers. Some experts favor the combination of lithium (Li) and carbamazepine (CBZ), based in part on early reports that the two cancel out some of each other’s side effects (eg, neutropenia and hyponatremia from CBZ, diabetes insipidus from Li; see TCPR, Nov/Dec 2018). This study compared Li+CBZ with an alternative strategy, Li+valproic acid (Li+VPA), in bipolar I disorder.

The independently funded study recruited 64 young adults with bipolar I from a tertiary referral center in Brazil. Of the 60 who were treated, 27 were depressed, 17 were hypomanic or manic, and 16 had mixed states. They were randomized to receive Li+VPA (n = 33) or Li+CBZ (n = 27), with each drug titrated to its therapeutic serum level. Only sertraline (given to a third of the depressed patients) and lorazepam were allowed as add-ons. The main outcome measure was reduction in bipolar symptoms, but tolerability was also key, using standard rating scales for each.

All patients were followed for 2 months with weekly to biweekly assessments, and responders (≤ 50% reduction in symptoms) were followed for 2 years to track remission. Neither response nor remission rates differed significantly between the two combinations. There was a non-significant trend favoring Li+VPA against mania and Li+CBZ against depression. Where the therapies differed was in tolerability. Li+VPA had significantly more side effects than Li+CBZ, particularly fatigue, decreased libido, and weight gain. After 2 months, the Li+VPA group gained an average of 4.6 pounds, while the average Li+CBZ patient lost half a pound.

The results were weakened, however, by the small sample size and high dropout rate. Less than half of those who entered the study made it through the first 2 months. The dropout rates were similar for both groups. Most dropouts either didn’t get better or left because of side effects.

TCPR’s Take
A high dropout rate and small sample size make these results tentative, but they suggest that CBZ may be more patient friendly than VPA when adding a mood stabilizer to lithium. Although CBZ does not interact with lithium, its other drug interactions can complicate the picture.


General Psychiatry
KEYWORDS bipolar_disorder lithium mania mood_stabilizers oxcarbazepine pharmacology psychopharmacology research research-update
Richard Moldawsky, MD

Is Ibogaine Safe for Opioid Detox?

More from this author
www.thecarlatreport.com
Issue Date: September 3, 2020
SUBSCRIBE NOW
Table Of Contents
CME Post-Test - When to Use Lithium, TCPR, September 2020
Highlights From This Issue
How COVID-19 Affects the Brain
Who Should Get Lithium?
Modern Challenges of Delusional Disorder
Two Augmentation Strategies Compared in Bipolar I
Confidentiality in a Time of COVID
DOWNLOAD NOW
Featured Book
  • MFB6eCover.jpg

    Medication Fact Book for Psychiatric Practice, Sixth Edition (2022)

    Guidance, clinical pearls, and bottom-line assessments covering the medications you use in your...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto4921771.jpg
    General Psychiatry

    Psychopharm Commandment #6: MAOIs

    MAOIs rank high in efficacy and are pretty well tolerated too, as long as you watch for two critical interactions.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.